SIX · ROP.SW
Roche Holding AG
CHF 403.50+CHF 1.80 (+0.45%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.57% below the high.
Loading market information…
SIX · RLF.SW · CHF
Stock price, earnings
Quote as of Dec 16, 2025, 06:56 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Relief Therapeutics Holding AG’s quoted price sits in the lower half of its reported 52-week range, 37.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Relief Therapeutics Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Relief Therapeutics Holding AG is a biopharmaceutical company, based in Geneva, Switzerland, and established in 2013. The firm is dedicated to providing therapeutic solutions for patients globally, including Switzerland, the rest of Europe, and North America, who suffer from serious diseases with significant unmet medical needs. The company's strategy centers on advancing clinical-stage programs, leveraging molecules that possess an established history of human use. These programs are backed either by initial data demonstrating human activity or efficacy, or by robust scientific rationale. Its primary investigational drug is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a diverse mechanism of action, designed to address various respiratory conditions. RLF-100 is currently undergoing Phase 3 clinical trials for COVID-19-induced acute respiratory distress syndrome and moderate-to-severe COVID-19 lung injury. Additionally, it is in Phase 1 clinical trials for acute lung injury in other intensive care settings and in Phase 2 trials for pulmonary sarcoidosis. Relief Therapeutics is also advancing ACER-001, a specialized powder formulation of sodium phenylbutyrate. This compound has successfully completed Phase 3 clinical trials for urea cycle disorders and is now in Phase 1 trials for maple syrup urine disease. Furthermore, the company is developing APR-TD011, a sprayable hypotonic acid-oxidizing solution, which is currently in Phase 2 clinical trials for epidermolysis bullosa.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 403.50+CHF 1.80 (+0.45%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.57% below the high.
CHF 133.48+CHF 1.18 (+0.89%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 0.76% below the high.
CHF 645.80+CHF 5.00 (+0.78%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
CHF 47.94+CHF 0.52 (+1.1%)
Avolta AG’s quoted price sits in the upper half of its reported 52-week range, 14.09% below the high.
CHF 15.32-CHF 0.28 (-1.79%)
Santhera Pharmaceuticals Holding AG’s quoted price sits in the upper half of its reported 52-week range, 18.68% below the high.
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
CHF 0.16+CHF 0.00 (+0.12%)
MindMaze Therapeutics Holding S.A.’s quoted price sits in the lower half of its reported 52-week range, 94.58% below the high.
CHF 2.17-CHF 0.08 (-3.56%)
EvoNext Holdings S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.8% below the high.
